<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02644252</url>
  </required_header>
  <id_info>
    <org_study_id>Toco-Pulm</org_study_id>
    <nct_id>NCT02644252</nct_id>
  </id_info>
  <brief_title>Tocotrienol as a Nutritional Supplement in Patients With Advanced Lung Cancer</brief_title>
  <acronym>Toco-Pulm</acronym>
  <official_title>Tocotrienol as a Nutritional Supplement in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vejle Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vejle Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is a need for improving the effect of first-line chemotherapy for lung cancer patients,
      preferably by using an approach with none or very few side effects.

      In this trial the investigators incorporate δ-tocotrienol/placebo as a nutritional supplement
      on top of standard chemotherapy for patients with advanced non-small cell lung cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>From date of randomization until date of first documented progression; assessed up to 36 months</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">190</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Performance status 0-1, Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: Cisplatin 75 mg/m2 plus vinorelbine 25 mg/m2. Day 8: Capsule vinorelbine 50 mg/m2. Tocotrienol 300 mg x 3 daily until progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Performance status 0-1, Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: Cisplatin 75 mg/m2 plus vinorelbine 25 mg/m2. Day 8: Capsule vinorelbine 50 mg/m2. Placebo 1 capsule x 3 daily until progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Performance status 2, Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: Carboplatin area under the curve (AUC)=5 plus vinorelbine 30mg/m2. Day 8: Capsule vinorelbine 60 mg/m2. Tocotrienol 300 mg x 3 daily until progression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Performance status 2, Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: Carboplatin area under the curve (AUC)=5 plus vinorelbine 30mg/m2. Day 8: Capsule vinorelbine 60 mg/m2. Placebo 1 capsule x 3 daily until progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Day 1: Cisplatin 75 mg/m2</intervention_name>
    <arm_group_label>Performance status 0-1, Arm A</arm_group_label>
    <arm_group_label>Performance status 0-1, Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Day 1: Vinorelbine 25 mg/m2</intervention_name>
    <arm_group_label>Performance status 0-1, Arm A</arm_group_label>
    <arm_group_label>Performance status 0-1, Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Day 8: Capsule vinorelbine 50 mg/m2</intervention_name>
    <arm_group_label>Performance status 0-1, Arm A</arm_group_label>
    <arm_group_label>Performance status 0-1, Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Day 1: Carboplatin AUC=5</intervention_name>
    <arm_group_label>Performance status 2, Arm A</arm_group_label>
    <arm_group_label>Performance status 2, Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Day 1: Vinorelbine 30 mg/m2</intervention_name>
    <arm_group_label>Performance status 2, Arm A</arm_group_label>
    <arm_group_label>Performance status 2, Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Day 8: Capsule vinorelbine 60 mg/m2</intervention_name>
    <arm_group_label>Performance status 2, Arm A</arm_group_label>
    <arm_group_label>Performance status 2, Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Tocotrienol 300 mg x 3 daily until progression</intervention_name>
    <arm_group_label>Performance status 0-1, Arm A</arm_group_label>
    <arm_group_label>Performance status 2, Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo 1 capsule x 3 daily until progression</intervention_name>
    <arm_group_label>Performance status 0-1, Arm B</arm_group_label>
    <arm_group_label>Performance status 2, Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed non-small cell lung cancer, including squamous cell
             carcinomas, adenocarcinomas and non-neuroendocrine large cell carcinomas

          -  Patients with advanced stages of NSCLC who are candidates to first-line platinum-based
             doublet chemotherapy

          -  Measurable disease by RECIST 1.1

          -  Age ≥ 18 years.

          -  Performance status 0-2.

          -  Adequate bone marrow function, liver function, and renal function (within 7 days prior
             to inclusion):

               -  White blood cells (WBC) ≥ 3.0 * 10^9/l or neutrophils (ANC) ≥ 1.5 * 10^9/l

               -  Platelet count ≥ 100 * 10^9/l

               -  Hemoglobin ≥ 6 mmol/l

               -  Serum bilirubin &lt; 2.0 * upper level of normal (ULN)

               -  Serum transaminase ≤ 2.5 * ULN

               -  Serum creatinine ≤ 1.5 ULN

          -  Written and orally informed consent.

        Exclusion Criteria:

          -  Other malignant diseases within 5 years prior to inclusion in the study, except
             curatively treated basal cell or squamous cell carcinoma of the skin and other types
             of cancer with minimal risk of recurrence.

          -  Other experimental therapy or participation in another clinical trial within 28 days
             prior to treatment initiation.

          -  Patients who have received prior chemotherapy for NSCLC

          -  Patients with NSCLC who are candidates to neoadjuvant chemotherapy or curative
             chemoradiotherapy

          -  Underlying disease not adequately treated (diabetes, cardiac disease)

          -  Allergy to the active substance or any of the auxiliary agents

          -  Pregnant or breast-feeding patients. For fertile women a negative pregnancy test at
             screening is mandatory.

          -  Fertile patients not willing to use effective methods of contraception during
             treatment and for 6 months after the end of treatment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christa H Nyhus, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Vejle Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christa H Nyhus, MD</last_name>
    <email>christa.haugaard.nyhus@rsyd.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Oncology, Vejle Hospital</name>
      <address>
        <city>Vejle</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christa H Nyhus, MD</last_name>
      <email>christa.haugaard.nyhus@rsyd.dk</email>
    </contact>
    <investigator>
      <last_name>Lisbeth Bertelsen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2015</study_first_submitted>
  <study_first_submitted_qc>December 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2015</study_first_posted>
  <last_update_submitted>August 3, 2017</last_update_submitted>
  <last_update_submitted_qc>August 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

